Immunomodulatory role of urolithin a on metabolic diseases

Ashley Mulcahy Toney, Darius Fox, Virginia Chaidez, Amanda E. Ramer-Tait, Soonkyu Chung

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations


Urolithin A (UroA) is a gut metabolite produced from ellagic acid-containing foods such as pomegranates, berries, and walnuts. UroA is of growing interest due to its therapeutic potential for various metabolic diseases based on immunomodulatory properties. Recent advances in UroA research suggest that UroA administration attenuates inflammation in various tissues, including the brain, adipose, heart, and liver tissues, leading to the potential delay or prevention of the onset of Alzheimer’s disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. In this review, we focus on recent updates of the anti-inflammatory function of UroA and summarize the potential mechanisms by which UroA may help attenuate the onset of diseases in a tissue-specific manner. Therefore, this review aims to shed new insights into UroA as a potent anti-inflammatory molecule to prevent immunometabolic diseases, either by dietary intervention with ellagic acid-rich food or by UroA administration as a new pharmaceutical drug.

Original languageEnglish (US)
Article number192
Pages (from-to)1-18
Number of pages18
Issue number2
StatePublished - Feb 2021


  • Inflammation
  • Insulin resistance
  • Lipid metabolism
  • Metabolic syndrome
  • Mitochondria
  • Nutri-tional sciences
  • Obesity
  • Urolithin A

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Immunomodulatory role of urolithin a on metabolic diseases'. Together they form a unique fingerprint.

Cite this